Responsiveness and construct validity of EPIC-26, AQoL-6D and SF-6D following treatment in prostate cancer. Bulamu NB, Mpundu-Kaambwa C, O'Callaghan M, Kaambwa B, et al. BMC Cancer 2023;23:297.

Read + Share

Amedeo Smart

Independent Medical Education

Read + Share

Bulamu NB, Mpundu-Kaambwa C, O'Callaghan M, Kaambwa B, et al. Responsiveness and construct validity of EPIC-26, AQoL-6D and SF-6D following treatment in prostate cancer. BMC Cancer 2023;23:297.
PMID: 37005587